Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...

Pharmaceuticals giant Merck & Company (MRK) has cut its full-year profit forecasts fearing a $200 million hit from President ...

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $2.01. Earnings, adjusted for one-time gains and costs, came to $2.22 per share. The results exceeded Wall Street ...

I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding ...

Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of Merck (MRK) with a Neutral rating and $85 price target Shares have been “a notable underperformer the past year” as the reset of ...

Merck MRK is a healthcare company that manufactures pharmaceutical products to treat various conditions in many therapeutic areas, including cardiometabolic disease, cancer and infections. Don't ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

It's a companion shot to Merck's Vaxneuvance (formerly V114), which covers 15 serotypes and was approved by the FDA last year as a rival to Pfizer's Prevnar 13 and newer Prevnar 20 vaccines, which ...

Drake University and Des Moines Area Community College could be close to a settlement agreement in a hotly contested legal battle over the schools' logos and trademarks. New court records show a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...